GlassScriptPhysician profile
Mathew Pulicken
NPI 1629231832
$2,309.48
in general payments reported to CMS, 2019-2025
33 companies · $18.89 in 2025
The $18.89 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $858 · 2020: $76.08 · 2021: $569 · 2022: $470 · 2023: $318 · 2025: $18.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $317.53 | 2023 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $259.72 | 2019-2022 | |
| Lilly USA, LLC | $215.46 | 2019-2022 | |
| Abbvie INC. | $170.54 | 2021 | |
| Biogen, INC. | $160.83 | 2019-2022 | |
| Neuropace, INC. | $124.99 | 2019 | |
| Amneal Pharmaceuticals LLC | $86.16 | 2019-2021 | |
| Genzyme Corporation | $82.86 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $81.02 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $72.67 | 2019-2022 | |
| Eisai INC. | $71.92 | 2022 | |
| Mdd US Operations, LLC | $69.22 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $61.22 | 2019 | |
| Acorda Therapeutics, INC | $50.90 | 2019 | |
| Ucb, INC. | $48.01 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $41.50 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $37.28 | 2021 | |
| Kyowa Kirin, INC. | $35.23 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $34.42 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.00 | 2022 | |
| Genentech USA, INC. | $24.68 | 2019 | |
| Lundbeck LLC | $24.53 | 2022 | |
| Allergan, INC. | $23.22 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $20.01 | 2022 | |
| Csl Behring | $20.00 | 2019 | |
| Tanabe Pharma America, INC. | $19.66 | 2020 | |
| Supernus Pharmaceuticals, INC. | $18.96 | 2021 | |
| Pfizer INC. | $18.89 | 2025 | |
| Amgen INC. | $18.55 | 2021 | |
| Livanova USA, INC. | $18.33 | 2021 | |
| Avanir Pharmaceuticals, INC. | $18.09 | 2022 | |
| Medtronic Vascular, INC. | $17.73 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Pulicken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.